Aspirin's Role Post-STEMI Heart Attack Questioned
The PREMIUM trial results indicate that monotherapy with prasugrel is not noninferior to standard dual antiplatelet therapy (DAPT) for patients following a STEMI heart attack. Consequently, the current medical guideline of using both a P2Y12 inhibitor and aspirin for 12 months remains the standard of care.
Why it matters
This study provides critical clinical evidence that prevents potentially unsafe changes to standard post-heart attack treatment protocols.
Dual antiplatelet therapy with a potent P2Y12 receptor inhibitor plus aspirin is recommended for up to 12 months in patients receiving a stent after an ST-segment elevation myocardial infarction (STEMI).
The PREMIUM trial compared a potent P2Y12 receptor inhibitor (prasugrel) without aspirin vs. a potent P2Y12 receptor inhibitor plus aspirin given at the time of percutaneous coronary intervention and for 12 months after.
The results of the trial do not support upfront aspirin omission.
Further studies are needed to determine the optimum antiplatelet regimen in patients after a STEMI.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in